Want to see FR:LNA full AI Analyst Report?
Top Page
LNA Sante SA
(LNA)
Select Model
Select Model
Rating:66Neutral
Price Target:
€37.00
▲(8.19% Upside)
Action:Reiterated
Date:07/01/26
Overall score is driven by stable operating fundamentals and strong cash generation, offset by meaningful leverage and thin net profitability. Technicals add support via a clear uptrend above key moving averages, while valuation appears reasonable with a modest dividend yield.
Positive Factors
Steady Revenue Growth
A sustained revenue-growth trend indicates ongoing demand for LNA Santé’s care facilities and services. Continued top-line expansion can support operating scale, absorb fixed costs and provide a foundation for durable cash generation.
Negative Factors
High Financial Leverage
Heavy leverage reduces financial flexibility and leaves the company more exposed to refinancing conditions and earnings volatility. Higher debt obligations may constrain investment capacity and increase the consequences of any sustained operating weakness.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
A sustained revenue-growth trend indicates ongoing demand for LNA Santé’s care facilities and services. Continued top-line expansion can support operating scale, absorb fixed costs and provide a foundation for durable cash generation.
Read all positive factors
LNA Sante SA (LNA) vs. iShares MSCI France ETF (EWQ)
Market Cap
€338.66M
Dividend Yield2.92%
Average Volume (3M)3.53K
Price to Earnings (P/E)13.8
Beta (1Y)0.41
Revenue Growth13.15%
EPS Growth10.30%
CountryFR
Employees8,976
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)2.35
Shares Outstanding10,709,416
10 Day Avg. Volume3,469
30 Day Avg. Volume3,531
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.28
P/FCF Ratio4.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.88
Revenue Forecast (FY)€990.29M
LNA Sante SA Business Overview & Revenue Model
Company Description
Established in 1990 and headquartered in Vertou, France, LNA Santé SA specializes in the administration and operation of a diverse portfolio of healthcare facilities. These include residences for the elderly, medical and rehabilitative care center...
How the Company Makes Money
null...
LNA Sante SA Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
44
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 912.67M | 806.60M | 736.09M | 728.22M | 689.49M |
| Gross Profit | 132.24M | 91.10M | 241.09M | 622.42M | 577.87M |
| EBITDA | 144.28M | 144.85M | 144.63M | 141.82M | 131.64M |
| Net Income | 24.14M | 21.82M | 23.41M | 25.81M | 23.51M |
Balance Sheet | |||||
| Total Assets | 1.60B | 1.54B | 1.51B | 1.51B | 1.53B |
| Cash, Cash Equivalents and Short-Term Investments | 94.83M | 75.06M | 77.17M | 101.98M | 152.12M |
| Total Debt | 907.25M | 936.51M | 887.67M | 911.55M | 1.00B |
| Total Liabilities | 1.26B | 1.21B | 1.20B | 1.21B | 1.31B |
| Stockholders Equity | 330.25M | 313.81M | 299.24M | 289.33M | 216.09M |
Cash Flow | |||||
| Free Cash Flow | 59.30M | 71.24M | 84.56M | 89.86M | 65.98M |
| Operating Cash Flow | 70.42M | 82.06M | 97.50M | 103.20M | 79.92M |
| Investing Cash Flow | -14.21M | -23.72M | -15.69M | -41.99M | -27.65M |
| Financing Cash Flow | -36.50M | -88.80M | -106.69M | -110.88M | -21.53M |
LNA Sante SA Technical Analysis
Neutral
34.20
Price Trends
34.40
Negative
32.47
Positive
28.45
Positive
Market Momentum
-0.44
Positive
39.99
Neutral
20.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:LNA, the sentiment is Neutral. The current price of 34.2 is above the 20-day moving average (MA) of 33.51, below the 50-day MA of 34.40, and above the 200-day MA of 28.45, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 39.99 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:LNA.
LNA Sante SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €455.48M | 13.98 | 8.57% | 5.19% | 2.78% | 187.96% | |
66 Neutral | €338.66M | 13.83 | 7.44% | 5.86% | 13.15% | 10.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €2.07B | -7.82 | -15.35% | 0.84% | 3.92% | 31.20% | |
49 Neutral | €160.89M | 5.50 | 33.68% | 0.58% | -11.89% | 1623.56% | |
49 Neutral | €1.18B | -20.48 | -4.25% | 11.04% | 2.65% | 10.24% | |
47 Neutral | €560.41M | -3.28 | -152.15% | ― | -27.19% | -117.39% |
* General Sector Average
FR:LNA
LNA Sante SA
32.50
3.87
13.50%
FR:BLC
Bastide le Confort Medical
22.00
-2.05
-8.52%
FR:BOI
Boiron SA
26.00
3.80
17.10%
FR:EMEIS
Orpea SA
12.82
2.07
19.26%
FR:GDS
Ramsay Generale de Sante
10.70
0.70
7.00%
FR:VLA
Valneva
2.96
-0.63
-17.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.